| Prev Close | 68.32 |
| Open | 68.57 |
| Day Low/High | 68.00 / 68.95 |
| 52 Wk Low/High | 65.06 / 100.23 |
| Volume | 8.09M |
| Avg Volume | 8.65M |
AbbVie Inc. (ABBV)
68.53
0.21
0.31
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 102.24B |
| EPS | 3.70 |
| P/E Ratio | 19.32 |
| Div & Yield | 4.28 (5.78%) |
This Was One Dismal Earnings Season
And it's hard to get excited about the second quarter, too.
Biotech Is Ripe for M&A: Analysts
After an asset price drop, large pharmaceutical companies are looking for strategic purchases.
2016 Sohn Investment Conference Live Blog: Session 1
Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.
Sohn Preview: What Will Larry Robbins, John Khoury & Carson Block Present Wednesday?
The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss Wednesday.
Cramer: Worst May Be Over for Embattled Pharma
The M&A activity is an incredible and a welcome sign.
Will Poor Earnings Bring Down the Market?
This earnings season continues to disappoint, and technology names are leading the downward charge.
Some Stocks Are Really Cheap
There are lots of winners in the first quarter.
Value, Yield a Must in 'Wade Boggs' Market
It's important to focus on hitting singles in this overbought and earnings-starved environment.
9 Health Names to Like Amid the Rhetoric
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
What Earnings Season Shows So Far
This will still be fourth quarter in a row that profits have declined year over year.
U.S. Futures Rise as Markets Look to Reverse Monday's Decline
U.S. indices look to reverse yesterday's losses as crude prices continue their climb.
3 Biotech Stocks to Buy Right Now
With low multiples and solid yields, these names look good for the long term.
AbbVie Is Rx for a Volatility Squeeze
ABBV is rising, and the current action could be the start of a strong move higher.
6 Stocks To Pick Up for the 2nd Quarter
In this choppy market, the sweet spot is large-caps with these three core attributes.
A Small Biotech Sells for Less Than Cash
And yet, Endocyte has a deep pipeline.
Biotech Stocks Are Beginning to Stir
I am starting to get more confident that the small caps are ready to bounce.
Betting on U.S. Economy Muddling Along
I like cheap smaller caps with little to no exposure to the global economy.
AbbVie's Triangle Chart Formation Is Pointed South
A breakdown below $52 should be the tipping point for further declines in ABBV.
Biotech Rally Is Healing Small-Caps
This sector is finally bouncing from deeply oversold levels.
My Takeaways and Observations
If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...
Silly Season Continues for Biotech
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
My Takeaways and Observations
I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here. Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...
Trump or Hillary? These Stocks Don't Care Who Wins
Some names should do well regardless of who becomes the next president.
Political Headwinds Hit the Market: Part 2
Some stocks should do well regardless of who is the next president.
I'm Mr. Brightside
I am not ready to go full "risk on," but it's nice to see the market out of its cage.
Bright Idea: Redeploy Some Utility Gains
The electrics have been crackling, but the group has more downside risk than currently perceived.
Play Strong Defense With 3 Big Biotechs
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.
